{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:59Z","timestamp":1786980299973,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00520-026-10445-z","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:37:39Z","timestamp":1771493859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)"],"prefix":"10.1007","volume":"34","author":[{"given":"Kazuaki","family":"Harada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hotaka","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhito","family":"Muranaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Sogabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Dazai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"5","key":"10445_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u2013495","journal-title":"Lancet Oncol"},{"key":"10445_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/601434","volume":"2011","author":"CL Donohoe","year":"2011","unstructured":"Donohoe CL, Ryan AM, Reynolds JV (2011) Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract 2011:601434","journal-title":"Gastroenterol Res Pract"},{"issue":"4","key":"10445_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/SPC.0b013e3283311d09","volume":"3","author":"JM Argil\u00e9s","year":"2009","unstructured":"Argil\u00e9s JM, Busquets S, Toledo M, L\u00f3pez-Soriano FJ (2009) The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 3(4):263\u2013268","journal-title":"Curr Opin Support Palliat Care"},{"issue":"2","key":"10445_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","volume":"10","author":"K Fearon","year":"2013","unstructured":"Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10(2):90\u201399","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10445_CR5","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/sj.bjc.6690590","volume":"80","author":"PT Todorov","year":"1999","unstructured":"Todorov PT, Field WN, Tisdale MJ (1999) Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer 80(11):1734\u20131737","journal-title":"Br J Cancer"},{"issue":"6","key":"10445_CR6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/bjc.1991.188","volume":"63","author":"SA Beck","year":"1991","unstructured":"Beck SA, Tisdale MJ (1991) Lipid mobilising factors specifically associated with cancer cachexia. Br J Cancer 63(6):846\u2013850","journal-title":"Br J Cancer"},{"issue":"2","key":"10445_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s13539-014-0142-1","volume":"5","author":"JB Hopkinson","year":"2014","unstructured":"Hopkinson JB (2014) Psychosocial impact of cancer cachexia. J Cachexia Sarcopenia Muscle 5(2):89\u201394","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"10445_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0959-8049(97)10090-9","volume":"34","author":"HJ Andreyev","year":"1998","unstructured":"Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34(4):503\u2013509","journal-title":"Eur J Cancer"},{"issue":"2","key":"10445_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","volume":"4","author":"VC Vaughan","year":"2013","unstructured":"Vaughan VC, Martin P, Lewandowski PA (2013) Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 4(2):95\u2013109","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"10445_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","volume":"7","author":"T Aoyagi","year":"2015","unstructured":"Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K (2015) Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol 7(4):17\u201329","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"10445_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y et al (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17(4):519\u2013531","journal-title":"Lancet Oncol"},{"issue":"8","key":"10445_CR12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","volume":"28","author":"D Currow","year":"2017","unstructured":"Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC (2017) ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 28(8):1949\u20131956","journal-title":"Ann Oncol"},{"issue":"8","key":"10445_CR13","first-page":"3495","volume":"24","author":"K Takayama","year":"2016","unstructured":"Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H et al (2016) Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer 24(8):3495\u20133505","journal-title":"Support Care Cancer"},{"issue":"3","key":"10445_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K et al (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124(3):606\u2013616","journal-title":"Cancer"},{"issue":"23","key":"10445_CR15","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H et al (2019) A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125(23):4294\u20134302","journal-title":"Cancer"},{"issue":"1","key":"10445_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jcsm.12675","volume":"12","author":"H Wakabayashi","year":"2021","unstructured":"Wakabayashi H, Arai H, Inui A (2021) The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. J Cachexia Sarcopenia Muscle 12(1):14\u201316","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9","key":"10445_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7170","volume":"13","author":"K Takayama","year":"2024","unstructured":"Takayama K, Kojima A, Honda C, Nakayama M, Kanemata S, Endo T et al (2024) Real-world safety and effectiveness of anamorelin for cancer cachexia: interim analysis of post-marketing surveillance in Japan. Cancer Med 13(9):e7170","journal-title":"Cancer Med"},{"key":"10445_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae086","author":"K Fujita","year":"2024","unstructured":"Fujita K, Akamine Y, Igarashi H, Fukushi Y, Sasaki K, Fukuda K et al (2024) Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyae086","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10445_CR19","volume":"31","author":"N Iwai","year":"2023","unstructured":"Iwai N, Sakai H, Oka K, Sakagami J, Okuda T, Hattori C et al (2023) Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study. Support Care Cancer 31(2):115","journal-title":"Support Care Cancer"},{"issue":"12","key":"10445_CR20","first-page":"621","volume":"31","author":"I Tsukiyama","year":"2023","unstructured":"Tsukiyama I, Iwata T, Takeuchi T, Kato RI, Sakuma M, Tsukiyama S et al (2023) Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia. Support Care Cancer 31(12):621","journal-title":"Support Care Cancer"},{"key":"10445_CR21","unstructured":"Ono parmaceutical Co. LAT, . Phar- maceutical and Medical Devices Agency (PMDA), Japan. https:\/\/www.info.pmda.go.jp\/go\/pack\/3999054F1028_1_02\/?view = frame&style=XML&lang=ja.(Japanese) Accessed 25 July 2023"},{"issue":"7","key":"10445_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/jso.21154","volume":"98","author":"Y Koike","year":"2008","unstructured":"Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K et al (2008) Preoperative C\u2010reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 98(7):540\u2013544","journal-title":"J Surg Oncol"},{"issue":"1","key":"10445_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/etm.2010.175","volume":"2","author":"Y Toiyama","year":"2011","unstructured":"Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M (2011) Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med 2(1):95\u2013101","journal-title":"Exp Ther Med"},{"issue":"8","key":"10445_CR24","first-page":"2341","volume":"23","author":"TW LeBlanc","year":"2015","unstructured":"LeBlanc TW, Samsa GP, Wolf SP, Locke SC, Cella DF, Abernethy AP (2015) Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). Support Care Cancer 23(8):2341\u20132347","journal-title":"Support Care Cancer"},{"key":"10445_CR25","unstructured":"Group. FAoCITF. Scoring of the FACIT measures. [Available from: https:\/\/www.facit.org\/scoring.\u00a0Accessed 17 Feb 2026"},{"issue":"6","key":"10445_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165(6):710\u2013718","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10445_CR27","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/jcsm.12761","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Song MM, Zhang X, Ding JS, Ruan GT, Zhang XW et al (2021) Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicentre cohort study. J Cachexia Sarcopenia Muscle 12(6):1466\u20131476","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10445_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12904-024-01538-9","volume":"23","author":"A Nishimura","year":"2024","unstructured":"Nishimura A, Hamauchi S, Notsu A, Fushiki K, Oshima K, Tsushima T et al (2024) Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia. BMC Palliat Care 23(1):214","journal-title":"BMC Palliat Care"},{"key":"10445_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031849","author":"C Panebianco","year":"2023","unstructured":"Panebianco C, Villani A, Potenza A, Favaro E, Finocchiaro C, Perri F et al (2023) Targeting gut microbiota in cancer cachexia: towards new treatment options. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24031849","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10445_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40780-024-00359-5","volume":"10","author":"H Fujii","year":"2024","unstructured":"Fujii H, Makiyama A, Nishimura K, Iihara H, Hirose C, Ohata K et al (2024) CONUT score as a predictor for anamorelin efficacy in patients with cancer cachexia receiving chemotherapy. J Pharm Health Care Sci 10(1):36","journal-title":"J Pharm Health Care Sci"},{"issue":"3","key":"10445_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41416-022-01826-2","volume":"127","author":"J McGovern","year":"2022","unstructured":"McGovern J, Dolan RD, Skipworth RJ, Laird BJ, McMillan DC (2022) Cancer cachexia: a nutritional or a systemic inflammatory syndrome? Br J Cancer 127(3):379\u2013382","journal-title":"Br J Cancer"},{"issue":"5","key":"10445_CR32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan DC (2013) The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 39(5):534\u2013540","journal-title":"Cancer Treat Rev"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10445-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:44:16Z","timestamp":1773215056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10445-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10445"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10445-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were conducted in accordance with the ethical standards of the Helsinki  Declaration of 1964 and its later versions. The study design and protocol received  approval from the Institutional Review Board of Hokkaido University Hospital and all  other participating institutions (approval number: 022-\u20130331). Due to the retrospective  nature of the study, the need for informed consent was waived. This research was  announced on a website (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Related to the subject matter, K. H, T. A, M. N, T. M, S. N, S. Y, and Y. K report honoraria from ONO PHARMACEUTICAL CO., LTD. outside the submitted work. Y. K reports research funding from ONO PHARMACEUTICAL CO., LTD. outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"221"}}